XML 40 R29.htm IDEA: XBRL DOCUMENT v3.26.3
Note 2 - Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2026
Notes Tables  
Segment Reporting [Table Text Block]
 

For the Nine Months Ended September 30,

 
 

2026

 

2025

 
 

Cardiac Electrophysiology

 

Private Aviation

 

Total

 

Total

 

Revenue, net

            

Luxe

 —  84  84  — 

Hops

 —  2,687  2,687  — 

Total revenues, net

 —  2,771  2,771  — 
             

Less:

            

Cost of revenues:

 —  2,424  2,424  — 

Acquired in-process research and development expense

 —  —  —  1,967 

Depreciation and amortization expense

 —  92  92  2 

Stock-based compensation expense

 491  —  491  195 

Salaries and benefits expense

 701  610  1,311  721 

Professional fees

 2,238  323  2,561  1,523 

Research and development expense

 —  —  —  2 

Marketing expense

 —  473  473  — 

Interest income

 (8) —  (8) (31)

Interest expense

 446  42  488  199 

Change in fair value of trading debt securities

 —  —  —  (117)

Change in fair value of minority equity interest

 2,302  —  2,302  — 

Change in fair value of deferred consideration

 (3,195) —  (3,195) — 

Change in fair value of deferred stock issuance liability

 (160) —  (160) — 

Loss on debt extinguishment

 105  —  105  — 

Gains on marketable securities, net

 (540) —  (540) — 

Income tax benefit

 (950) —  (950) (1,596)

Other segment items (1)

 1,216  860  2,076  1,081 

Segment and consolidated loss from continuing operations

$(2,646)$(2,053)$(4,699)$(3,946)
 

For the Three Months Ended September 30,

 
 

2026

 

2025

 
 

Cardiac Electrophysiology

 

Private Aviation

 

Total

 

Total

 

Revenues, net

            

Luxe

 —  15  15  — 

Hops

 —  1,823  1,823  — 

Total revenues, net

 —  1,838  1,838  — 
             

Less:

            

Cost of revenues

 —  1,514  1,514  — 

Acquired in-process research and development expense

 —  —  —  — 

Depreciation and amortization expense

 —  40  40  1 

Stock-based compensation expense

 161  —  161  52 

Salaries and benefits expense

 231  323  554  239 

Professional fees

 587  160  747  527 

Research and development expense

 —  —  —  — 

Marketing expense

 —  320  320  — 

Interest income

 (2) —  (2) (10)

Interest expense

 165  —  165  83 

Change in fair value of trading debt securities

 —  —  —  (107)

Change in fair value of minority equity interest

 —  —  —  — 

Change in fair value of deferred consideration

 —  —  —  — 

Change in fair value of deferred stock issuance liability

 (206) —  (206) — 

Loss on debt extinguishment

 —  —  —  — 

Gains on marketable securities, net

 (162) —  (162) — 

Income tax benefit

 (463) —  (463) 78 

Other segment items (1)

 608  415  1,023  372 

Segment loss from continuing operations

 (919) (934) (1,853) (1,235)
Fair Value, by Balance Sheet Grouping [Table Text Block]
    

September 30, 2026

    
 

Total

 

Level 1

 

Level 2

 

Level 3

 

Assets:

            

Cash equivalents

            

Money market funds

$342 $342 $— $— 

Total assets

$342 $342 $— $— 
             

Liabilities:

            

Royalties payable - continuing operations

$160 $— $— $160 

Royalties payable due to related parties - discontinued operations

 632  —  —  632 

Total liabilities

$792 $— $— $792 
      

December 31, 2025

     
  

Total

  

Level 1

  

Level 2

  

Level 3

 

Assets:

                

Cash Equivalents

                

Money market funds

 $2  $2  $—  $— 

Total assets

 $2  $2  $—  $— 
                 

Liabilities:

                

Royalties payable - continuing operations

 $160  $—  $—  $160 

Royalties payable due to related parties - discontinued operations

  632   —   —   632 

Convertible notes payable

  298   —   —   298 

Total liabilities

 $1,090  $—  $—  $1,090 
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
 

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

 
 

Royalties Payable

 

Deferred Stock Issuance Liability

 

Deferred Consideration

 

Convertible Notes Payable

 

Balance at January 1, 2026

$160 $— $— $298 

Fair value at issuance

 —  —  11,028  — 

Change in fair value

 —  —  (2,877) — 

Balance at March 31, 2026

 160  —  8,151  298 

Fair value at issuance

 —  601  —  — 

Change in fair value

 —  46  (318) — 

Settlement of financial instruments

 —  —  (7,833) (403)

Realized (gains) and losses

 —  —  —  105 

Balance at June 30, 2026

 160  647  —  — 

Change in fair value

 —  (206) —   

Settlement of financial instrument

 —  (441) —  — 

Balance at September 30, 2026

$160 $— $— $— 
 

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

 
 

Royalties Payable

 

Trading Debt Securities

 

Balance at January 1, 2025

$160 $— 

Change in fair value

 —  — 

Balance at March 31, 2025

 160  — 

Purchased

 —  864 

Change in fair value

 —  10 

Balance at June 30, 2025

 160  874 

Change in fair value

 —  107 

Balance at September 30, 2025

$160 $981 
Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]

Computer hardware and software

  1 - 5 years 

Furniture, fixtures and equipment

  7 years 

Capitalized software development costs

  5 years 
Disaggregation of Revenue [Table Text Block]
 

For the Three Months Ended September 30,

 

For the Nine Months Ended September 30,

 
 

2026

 

2025

 

2026

  

2025

 

Revenue

             

US

$1,813 $— $2,746  $— 

International

 25  —  25   — 

Total Revenue

$1,838 $— $2,771  $— 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
  

Nine Months Ended September 30,

 
  

2026

  

2025

 

Deferred revenue, beginning of period

 $—  $— 

Deferred revenue assumed as part of acquisition (see Note 3)

  171   — 

Revenue recognized from deferred revenue during the period

  (206)  — 

Additional amounts billed or received and deferred during the period

  265   — 

Deferred revenue, end of period

 $230  $— 
Royalties Payable [Member]  
Notes Tables  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

Instrument

Valuation Technique

Unobservable Input

Input Range

 

Royalties payable

Discounted future cash flows

Revenue adjusted discount rate

 19.5%